Medrogestone

Medrogestone

Endocrine, paracrine and intracrine mechanisms of growth regulation in normal and malignant breast epithelium

Published in A. R. Genazzani, Hormone Replacement Therapy and Cancer, 2020

Various progesterone derivatives (e.g. medrogestone), as well as norprogestins (e.g. nomegestrol acetate, promegestone) provoke a significant decrease of estradiol formation when physiological concentrations of estrone sulfate are incubated with breast cancer cells (MCF-7 and T-47D)46,49–51. Figure 1 compares the inhibitory effects of different progestins in the conversion of estrone sulfate to estradiol in T-47D hormone-dependent breast cancer cells.

The progestin-only pills drospirenone 4 mg and desogestrel 0.075 mg as an option for the management of dysmenorrhea and mastodynia

View Article

Journal Information

Published in Gynecological Endocrinology, 2022

Pedro-Antonio Regidor, Enrico Colli

Dydrogesterone and medrogesterone have been used in a controlled trial by Winkler et al. [33]. They could show that under the use of 10 mg/day from day 14 to day 25 for six cycles, 75% of the patients treated with dydrogesterone and 86% of the patients treated with medrogestone were completely pain-free.

Explore chapters and articles related to this topic

Endocrine, paracrine and intracrine mechanisms of growth regulation in normal and malignant breast epithelium

The progestin-only pills drospirenone 4 mg and desogestrel 0.075 mg as an option for the management of dysmenorrhea and mastodynia